Mema Eralda, Cho Emma, Ryu Yun-Kyoung, Jadeja Priya, Wynn Ralph, Taback Brett, Ha Richard
Department of Radiology, Columba University Medical Center, New York, NY.
Department of Radiology, Columba University Medical Center, New York, NY.
Curr Probl Diagn Radiol. 2019 Mar-Apr;48(2):117-120. doi: 10.1067/j.cpradiol.2017.12.007. Epub 2018 Jan 9.
To evaluate whether in the setting of negative diagnostic mammogram for breast pain additional ultrasound is necessary.
Retrospective IRB-approved review of our database identified 8085 women who underwent ultrasound evaluation for breast pain from 1/1/2013-12/31/2013. Of 8085 women, 559 women had mammogram evaluation preceding the ultrasound and these women comprise the basis of this study. The patient's age, type of mammogram examination (screening or diagnostic), Breast Imaging-Reporting and Data System (BI-RADS) breast density (BD), type of breast pain (focal, diffuse, cyclical, unilateral, bilateral), additional breast symptoms (palpable concern, nipple discharge, skin changes, others), mammogram or ultrasound findings and final BI-RADS assessment, follow-up imaging, and follow-up biopsy results were reviewed and recorded.
The median age of patients was 46 years old (range: 27-97). Patients recalled from negative screening mammogram were 29.8% (167/559). Patients with preceding negative diagnostic mammogram were 70.2% (392/559). The BI-RADS BD distribution was BD1: 5.5%, BD2: 39.9%, BD3: 46.0%, BD4: 8.6%. Final BI-RADS assessments were BI-RADS 1/2 (79%), BI-RADS 3 (12.9%), BI-RADS 4 (8.1%), BI-RADS 5 (0%). Majority (66.9%, 374/559) of the patient had breast pain alone. Additional breast symptoms were also noted as follows: palpable concern (24%), nipple discharge (3.9%), skin changes or other (5.2%). On follow-up evaluation, 26 findings were recommended for tissue sampling yielding 2 malignancies (0.4%, 2/559) in 2 patients. In the setting of negative mammogram and clinical symptom of breast pain alone yielded no malignances (NPV, 100%, 374/374) and was not impacted by BD. In patients with additional symptoms accompanying pain, malignancies were present despite negative mammogram in 2 patients; nipple discharge (4.5%, 1/22), and palpable concern (0.7%, 1/134).
In the setting of negative mammogram and breast pain alone, additional evaluation with ultrasound is likely low yield and may be unnecessary. However, with additional symptoms such as palpable concern or nipple discharge, ultrasound is likely an important adjunct modality for identifying mammographically occult tumors.
评估在乳腺钼靶检查对乳腺疼痛诊断为阴性的情况下,是否有必要进一步进行超声检查。
经机构审查委员会(IRB)批准,对我们的数据库进行回顾性分析,确定了2013年1月1日至2013年12月31日期间因乳腺疼痛接受超声检查的8085名女性。在这8085名女性中,有559名女性在超声检查前进行了钼靶检查,这些女性构成本研究的基础。记录并审查了患者的年龄、钼靶检查类型(筛查或诊断)、乳腺影像报告和数据系统(BI-RADS)乳腺密度(BD)、乳腺疼痛类型(局限性、弥漫性、周期性、单侧、双侧)、其他乳腺症状(可触及肿物、乳头溢液、皮肤改变等)、钼靶或超声检查结果以及最终的BI-RADS评估、随访影像检查和随访活检结果。
患者的中位年龄为46岁(范围:27 - 97岁)。因筛查钼靶检查阴性而召回的患者占29.8%(167/559)。之前诊断性钼靶检查为阴性的患者占70.2%(392/559)。BI-RADS BD分布为:BD1:5.5%,BD2:39.9%,BD3:46.0%,BD4:8.6%。最终的BI-RADS评估为:BI-RADS 1/2(79%),BI-RADS 3(12.9%),BI-RADS 4(8.1%),BI-RADS 5(0%)。大多数患者(66.9%,374/559)仅有乳腺疼痛。还记录到的其他乳腺症状如下:可触及肿物(24%)、乳头溢液(3.9%)、皮肤改变或其他(5.2%)。在随访评估中,26项检查结果建议进行组织取样,2例患者发现2处恶性病变(0.4%,2/559)。在钼靶检查阴性且仅有乳腺疼痛临床症状的情况下未发现恶性病变(阴性预测值,100%,374/374),且不受BD影响。在伴有疼痛且有其他症状的患者中,尽管钼靶检查阴性,仍有2例患者发现恶性病变;乳头溢液(4.5%,1/22),可触及肿物(0.7%,1/134)。
在钼靶检查阴性且仅有乳腺疼痛的情况下,进一步进行超声检查可能收益较低,或许没有必要。然而,对于伴有可触及肿物或乳头溢液等其他症状的情况,超声检查可能是识别钼靶隐匿性肿瘤的重要辅助手段。